1 / 5

key points: nams 2004 position statement on vasomotor symptoms

First consider lifestyle changes aloneAdd nonprescription remedy, such as:dietary isoflavonesblack cohosh or vitamin EAlthough insufficient clinical trial evidence to support efficacy of these optionsBut they are reasonable approaches given lack of potential short-term adverse effectsIt is not known whether isoflavone supplements can be safely consumed by women with breast cancer.

oshin
Télécharger la présentation

key points: nams 2004 position statement on vasomotor symptoms

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Key Points: NAMS 2004 Position Statement on Vasomotor Symptoms The North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004.

    2. First consider lifestyle changes alone Add nonprescription remedy, such as: dietary isoflavones black cohosh or vitamin E Although insufficient clinical trial evidence to support efficacy of these options But they are reasonable approaches given lack of potential short-term adverse effects It is not known whether isoflavone supplements can be safely consumed by women with breast cancer

    3. Prescription systemic hormone therapy, either as combined estrogen-progestogen therapy (EPT) or estrogen (ET) for women after hysterectomy, remains the gold standard for treatment in women without contraindications Oral contraceptives are an option for perimenopausal women, especially those needing contraception

    4. Options for women with concerns relating to estrogen- containing treatments include lifestyle modification combined with one of the following, provided there are no contraindications: The antidepressants venlafaxine, paroxetine, or fluoxetine Gabapentin Progestogens, although no definitive data are available on long-term safety in women with a history of breast cancer Clonidine or methyldopa, but they are limited by only moderate efficacy combined with a relatively high rate of adverse events

    5. Regardless of management option utilized, treatment should be periodically evaluated to determine if it is still necessary In almost all women, menopause-related vasomotor symptoms will abate over time without any intervention

More Related